MAP to Provide Access to Nilotinib, for Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
NCT04559555 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2022-08-09
Summary
The purpose of this Cohort Treatment Plan is to allow access to nilotinib for eligible patients diagnosed with relapsed or refractory Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL).
Conditions
- Acute Lymphoblastic Leukemia (ALL)
Interventions
- DRUG
-
Nilotinib
The compassionate use dose of nilotinib is 400 mg orally twice daily and should not be taken with food
Sponsors & Collaborators
- lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
Nilotinib Pre and Post Allogeneic Stem Cell Transplantation
NCT00750659 ·Status: COMPLETED ·Phase: PHASE2
-
Nilotinib in Newly Diagnosed Adult Philadelphia Chromosome & /or BCR-ABL Positive Chronic Myeloid Leukaemia in Chronic Phase
NCT01061177 ·Status: COMPLETED ·Phase: PHASE4
-
A Phase l/ll Study of AMN107 in Adult Patients With Glivec-intolerant CML or Relapsed-refractory Ph+ALL
NCT00384228 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study to Assess Efficacy and Safety of Nilotinib 300mg Twice Daily in Patients With Philadelphia Positive Chronic Myeloid Leukaemia (CML) in Chronic Phase Who Are Intolerant to Prior Tyrosine Kinase Inhibitors.
NCT02108951 ·Status: TERMINATED ·Phase: PHASE3
-
Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients
NCT01254188 ·Status: COMPLETED ·Phase: PHASE3
-
Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT01076556 ·Status: TERMINATED ·Phase: PHASE1
-
Nilotinib With Chemotherapy for the Treatment of Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
NCT00905398 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
NCT01142427 ·Status: COMPLETED
-
Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia
NCT01670084 ·Status: WITHDRAWN ·Phase: PHASE2
-
Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response
NCT01043874 ·Status: COMPLETED ·Phase: PHASE4
-
Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia
NCT01914484 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients
NCT01784068 ·Status: COMPLETED ·Phase: PHASE2
-
Nilotinib + Pegylated Interferon Alpha 2a for Untreated Chronic Phase Chronic Myelogenous Leukemia
NCT01294618 ·Status: COMPLETED ·Phase: PHASE2
-
Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT)
NCT04716075 ·Status: COMPLETED ·Phase: PHASE2
-
BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL
NCT04690595 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Liposome-encapsulated Daunorubicin-Cytarabine, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT02642965 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
NCT02819804 ·Status: TERMINATED ·Phase: PHASE1
-
Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients.
NCT01844765 ·Status: COMPLETED ·Phase: PHASE2
-
Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML)
NCT00129740 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma
NCT03505554 ·Status: UNKNOWN ·Phase: PHASE2
-
Asciminib Maintenance Therapy Following alloHCT or CAR T to Prevent Relapse in Adults With Ph+ALL
NCT07250087 ·Status: RECRUITING ·Phase: PHASE1
-
Expanded Access Program of Ponatinib
NCT01592136 ·Status: APPROVED_FOR_MARKETING
-
Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib
NCT00644878 ·Status: TERMINATED ·Phase: PHASE2
-
Lenalidomide and Alvocidib in Treating Patients With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT00735930 ·Status: COMPLETED ·Phase: PHASE1
-
Nilotinib and LDE225 in the Treatment of Chronic or Accelerated Phase Myeloid Leukemia in Patients Who Developed Resistance to Prior Therapy
NCT01456676 ·Status: COMPLETED ·Phase: PHASE1